Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) – Research analysts at Cantor Fitzgerald boosted their FY2018 EPS estimates for Valeant Pharmaceuticals Intl in a research report issued on Tuesday, May 22nd. Cantor Fitzgerald analyst L. Chen now expects that the specialty pharmaceutical company will earn $3.13 per share for the year, up from their previous estimate of $2.97. Cantor Fitzgerald has a “Buy” rating and a $25.00 price objective on the stock.
Several other analysts also recently issued reports on the stock. Mizuho raised shares of Valeant Pharmaceuticals Intl from an “underperform” rating to a “neutral” rating and boosted their target price for the company from $10.00 to $15.00 in a research note on Friday, April 6th. Zacks Investment Research raised shares of Valeant Pharmaceuticals Intl from a “sell” rating to a “hold” rating in a research note on Monday, April 2nd. Deutsche Bank set a $20.00 target price on shares of Valeant Pharmaceuticals Intl and gave the company a “buy” rating in a research note on Wednesday, March 21st. Goldman Sachs initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, January 24th. They set a “sell” rating and a $18.00 target price on the stock. Finally, JPMorgan Chase set a $13.00 target price on shares of Valeant Pharmaceuticals Intl and gave the company a “sell” rating in a research note on Wednesday, May 9th. Five analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $19.30.
Shares of NYSE:VRX opened at $22.03 on Wednesday. The company has a debt-to-equity ratio of 5.59, a quick ratio of 0.92 and a current ratio of 1.18. Valeant Pharmaceuticals Intl has a 12-month low of $10.94 and a 12-month high of $24.43. The firm has a market cap of $7.73 billion, a price-to-earnings ratio of 5.75, a PEG ratio of 0.44 and a beta of -0.35.
Valeant Pharmaceuticals Intl (NYSE:VRX) (TSE:VRX) last announced its earnings results on Tuesday, May 8th. The specialty pharmaceutical company reported $0.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.29. Valeant Pharmaceuticals Intl had a negative net margin of 10.65% and a positive return on equity of 27.87%. The company had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.95 billion. During the same period in the previous year, the business earned $1.79 EPS. The company’s revenue was down 5.4% on a year-over-year basis.
In other Valeant Pharmaceuticals Intl news, Director Schutter Richard U. De acquired 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was purchased at an average cost of $15.34 per share, for a total transaction of $153,400.00. Following the completion of the acquisition, the director now owns 106,062 shares of the company’s stock, valued at approximately $1,626,991.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Schutter Richard U. De acquired 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 15th. The stock was acquired at an average price of $21.83 per share, with a total value of $327,450.00. The disclosure for this purchase can be found here. Insiders purchased 7,136,629 shares of company stock valued at $110,029,937 over the last quarter. 11.54% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. Rational Advisors LLC bought a new stake in Valeant Pharmaceuticals Intl in the first quarter worth $1,312,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp boosted its holdings in Valeant Pharmaceuticals Intl by 1,533.2% in the first quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 501,400 shares of the specialty pharmaceutical company’s stock worth $10,284,000 after purchasing an additional 470,700 shares in the last quarter. Tuttle Tactical Management bought a new stake in Valeant Pharmaceuticals Intl in the first quarter worth $1,312,000. Alpine Global Management LLC boosted its holdings in Valeant Pharmaceuticals Intl by 24.6% in the first quarter. Alpine Global Management LLC now owns 41,750 shares of the specialty pharmaceutical company’s stock worth $665,000 after purchasing an additional 8,250 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Valeant Pharmaceuticals Intl by 16.9% in the first quarter. Millennium Management LLC now owns 496,313 shares of the specialty pharmaceutical company’s stock worth $7,901,000 after purchasing an additional 71,900 shares in the last quarter. Hedge funds and other institutional investors own 50.13% of the company’s stock.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.